Last reviewed · How we verify

Zometa — Competitive Intelligence Brief

Zometa (Zometa) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Zometa (Zometa) — University of Arkansas.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Zometa TARGET Zometa University of Arkansas marketed Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
Zoledronate Zoledronate Children's Hospital Medical Center, Cincinnati marketed Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zometa — Competitive Intelligence Brief. https://druglandscape.com/ci/zometa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: